Multiple sclerosis is a chronic and autoimmune inflammatory disease that affects the central nervous system (CNS), particularly the communication between the brain and other parts of the body. It is a specific type of demyelinating disease that damages the insulating coating of nerve cells in the brain & spinal cord. There is usually no treatment for MS, general care is based on quick recovery from damage that delays the disease progression and manages the MS symptoms.
The symptoms of MS vary widely and depend on the extent of nerve damage and the shape & position of the nerves affected. The symptoms of MS include numbness or weakness of the extremities generally on one side of the body, partial or the total sight loss, twice the view and the feeling of electric shock in some neck movements, the tremor and the lack of balance or equilibrium mode. Extreme MS can impair the ability to walk independently or result in complete disability. The main causes of MS are problems with walking & balance, fatigue, blurred vision, muscle weakness, but symptoms of MS vary from patient to patient. Growing number of patients, increased screening tests, and requirement for better care options are believed to be the main drivers for the growth of the MS treatment market over the forecast period.
As per analysis, Europe Multiple Sclerosis Drugs Market 2020-2027 by Drug Type (Immunomodulators, Immunosuppressants), Drug Class, Drug Category (Large-molecule, Small-molecule), Route of Administration (Oral, Parenteral), MS Type (RRMS, PPMS, SPMS, PRMS), Distribution Channel, and Country Trend Outlook and Growth Opportunity. Some of the key companies operating in the Europe multiple sclerosis drugs market include Bristol-Myers Squibb Company, Acorda Therapeutics Inc., Biogen Inc., Abbvie, Inc., Pfizer Inc., Merck KgaA, Teva Pharmaceutical Industries Ltd., Novartis AG, Bayer AG, F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Mylan NV, Sanofi SA and among others. The major companies in the multiple sclerosis drugs market have been profiled based on key aspects for instance company overview, financial overview, product portfolio, recent developments, and competitive business strategies.
In terms of drug type, Europe multiple sclerosis drugs market can be categorized as immunomodulators (Betaseron/Extavia, Copaxone, Gilneya, Avonex/Plegridy, Tysabri, Rebif, Tecifidera and Ampyra) and immunosuppressants (Zinbryta, Lemtrada, Aubagio, Ocrelizumab and others). In terms of drug class, market can be categorized as Sphingosine 1 Phosphate Receptor Modulators, Monoclonal Antibodies, NF-?B Inhibitor, Interferon Beta, Mixed Polymers, Adrenocorticotropic Hormone, Corticosteroids and others. In terms of drug category, market can be categorized as small-molecule drugs and large-molecule drugs. Additionally, in term of MS type, market can be categorized as Primary progressive MS (PPMS), Secondary progressive MS (SPMS), Relapsing-remitting MS (RRMS) and Progressive-relapsing MS (PRMS). RRMS segment is predicted to exhibit substantial growth rate as it is most common form of multiple sclerosis at onset during the forecast period.
Europe region is projected to grow with highest growth rate owing to introduction of brand new treatment options for multiple sclerosis in the region during the forecast period. Germany dominates the European market for the treatment of multiple sclerosis with increasing research & development (R&D) for drug development in the region. France country is also dominates the multiple sclerosis drugs industry attributable to people’s awareness regarding multiple sclerosis & its treatment.
For More Information, click on the link below:-
Europe Multiple Sclerosis Drugs Market Research Report
Related Report:-
Contact Us:-
Ken Research
Ankur Gupta, Head Marketing & Communications
+91-9015378249
